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Summary
We report a general method to examine the recognition of post-translational modifications (PTMs)
by antibodies and proteins. We use this method to evaluate the binding of modification-specific
antibodies and chromatin-associating factors to an array of high-purified, biotinylated peptides
(derived from human histone sequences) harboring multiple PTMs printed onto streptavidin-
coated glass slides. We find that modification-specific antibodies are both more promiscuous in
their PTM recognition than expected and highly influenced by neighboring PTMs. Binding of
chromatin-associating factors is also influenced by combinatorial PTMs, giving further support for
the “Histone Code” hypothesis. Thus we report the first thorough characterization of PTM
influence on antibody recognition and describe a tool for the rapid and inexpensive assessment of
chromatin-associating factor binding specificity.
Results and Discussion
Post-translational modifications (PTMs) of proteins such as phosphorylation, methylation,
acetylation, and ubiquitination regulate many processes such as protein degradation, protein
trafficking, and mediation of protein-protein interactions[1]. Perhaps the best-studied PTMs
are those found associated with histone proteins. More than one hundred histone PTMs have
been described and they largely function by recruiting protein factors to chromatin, which in
turn, drive processes such as transcription, replication, and DNA repair[2]. Likewise, dozens
of chromatin-associating factors have been identified that bind to particular histone PTMs
and hundreds of modification-specific histone antibodies have been developed to understand
the in vivo function of these modifications[3].
The enormous number of potential combinations of histone PTMs represents a major
obstacle toward our understanding of how PTMs regulate chromatin-templated processes, as
well as our ability to develop high-quality diagnostic tools for chromatin and epigenetic
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studies. The same obstacle applies to other proteins regulated by combinatorial PTMs – for
example, p53, RNA polymerase, or nuclear receptors[4-6]. To that end, we developed a
peptide array-based platform to begin to address how both proteins and antibodies recognize
combinations of PTMs. We focused primarily on the recognition of PTMs associated with
the N-terminal tail of histone H3, but this approach is useful for the study of other histone
modifications and combinatorial PTMs found on other proteins.
We generated a library of 110 synthetic histone peptides bearing either single or
combinatorial PTMs and a biotin moiety for immobilization (Figure 1 and Table S2). Prior
to printing, all peptides were subjected to rigorous quality control to verify their accuracy
(see http://www.med.unc.edu/~bstrahl/Arrays/index.htm for complete details). This is
significant, as extensive peptide purification and mass spectrometric analysis is not possible
with other recently described array technologies used to study combinatorial histone
PTMs[7]. Another significant advancement in our method was the introduction of a
biotinylated fluorescent tracer molecule, which served as a positive control for the quality of
our printing in all experiments. Lastly, peptides were printed as a series of 6 spots, two times
per slide by two different pins, yielding 24 independent measurements of every binding
interaction per slide. These measures were adopted to minimize binding artifacts due to pin
variation or inconsistencies on slide surface. Thus, these arrays and the technical approaches
described herein are the first to offer a large number of extensively characterized histone
peptide substrates suitable for the assessment of protein or antibody binding.
We initially used our arrays to ask two fundamental questions regarding the recognition of
histone PTMs: 1) How well do modification-directed antibodies recognize their intended
epitope? and 2) what impact, if any, do combinatorial PTMs have on antibody recognition?
We tested more than 20 commercially available antibodies raised against individual
modifications on histone tails (see Table S4 and
http://www.med.unc.edu/~bstrahl/Arrays/index.htm for experimental conditions and
complete datasets). Generally, we found that antibodies were reasonably proficient at
recognizing their target modification (Figure S3) however we found several exceptions –
notably the discrimination between different methyllysine states by methyl-specific
antibodies and the recognition of histone H3 lysine 14 acetylation (H3K14ac).
To explore methyllysine recognition, we tested the specificity of commercial antibodies
raised against the three different methylated forms (mono-, di-, and trimethyl) of H3 at
lysine 4 and 79 (H3K4me and H3K79me) (Figure 2). These antibodies were generally
specific for their target lysine residue - however, both the trimethyl- and dimethyl-directed
antibodies show measurable cross-reactivity with dimethyllysine and monomethyllysine,
respectively (Figure 2A and Figure S1). This finding has particular biological importance,
as each methylation state of a given histone lysine residue is thought to mediate different
biological outcomes through the recruitment of distinct chromatin-associated factors[8]. For
example, H3K4me3 is well correlated with transcriptional activation through the recruitment
of histone acetyltransferases and the preinitiation complex of transcription[9-11].
Conversely, H3K4me2 was reported to recruit the Set3 histone deacetylase complex[8]. The
ability to distinguish between these methyl states is therefore necessary to dissect how H3K4
methylation controls the balance of histone acetylation/deacetylation at transcribed genes.
We also tested a number of antibodies raised against acetyllysine found at position 14 of
histone H3 (H3K14ac). Unlike lysine methylation, our arrays detected that several of these
antibodies had difficulty in recognizing their target sequence, preferring acetylation at lysine
36 (H3K36ac) instead (Figure 2B). Additionally, peptide competition assays verified the
interaction between the H3K14 antibodies and the H3K36ac peptide (Figure 2D). This result
is likely explained by the fact that H3K14 and H3K36 are found in very similar sequence
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contexts and are acetylated by the same enzyme in vivo (Figure 2C). Acetylation of both
H3K14 and H3K36 is catalyzed by the histone acetyltransferase Gcn5[12], however,
H3K14ac is reported to be recognized by the RSC complex in yeast whereas H3K36ac has
been reported to be recognized by the bromodomain of PCAF in human cells[13, 14]. Thus
misdetection of H3K36ac using H3K14ac-directed antibodies by either western blot or
chromatin immunoprecipitation may have implication for the studies of chromatin-templated
processes regulated by H3K14 acetylation.
The large number of synthetic peptides containing combinatorial PTMs allowed us to also
ascertain how PTM recognition is influenced by neighboring modifications. We therefore
did further analysis of the H3K4me3 antibodies to determine how adjacent modifications
affect substrate recognition. We observed that a monoclonal antibody widely used against
H3K4me3 (Abcam; cat # ab1012) is perturbed mainly by modification at Histone H3
arginine 2 (H3R2) (Figure 3A). Contrastingly, a widely used polyclonal antibody from
Millipore (#07-473) was negatively influenced by H3T6 phopshorylation and a similar
antibody from Active Motif (#39160) was not particularly sensitive to any neighboring
modification (Figure 3A).
We also examined the well-characterized PTM “switch” region on histone H3, where H3K9
is modified by either acetylation or methylation and the neighboring serine 10 (H3S10) is a
target for phosphorylation[15]. A polyclonal antibody (Active Motif; #39253) raised against
H3S10 phosphorylation showed a statistically significant reduction in binding to peptides
also modified at H3K9 (Figure 3B and 3C). In contrast, an antibody raised against both
H3S10phos and H3K9ac (Cell Signaling; #9711) showed nearly absolute specificity for the
peptide containing both modifications (Figure 3B and 3C). These data can be interpreted to
suggest that biological changes in acetylation and methylation at H3K9 would influence the
ability of antibodies derived against H3S10 phosphorylation to appropriately detect this
mark. Such findings are significant, as H3S10 phopshorylation levels have already been
correlated to change during the cell cycle, and in response to histone deacetylase inhibitors
[16-18].
Collectively, our analysis of histone PTM-specific antibodies enabled us to uncover
recognition of related but “off” target sequences, in addition to adjacent PTM affects. To our
knowledge this is the first major assessment of how neighboring PTMs influence the
recognition of histone PTM-specific antibodies. Given other proteins are predicted to have
PTM “codes” within their sequences that regulate activity, our work has potential
implications in other areas of biological regulation as well [19].
In addition to being a powerful diagnostic tool for the characterization of PTM-derived
antibodies, we used our peptide array technology to measure how PTM codes affect the
interaction of chromatin-associated proteins. Accordingly, we measured the binding of
several domains known to interact with H3K4me3. We found that the PHD domain from the
VDJ recombination factor Rag2 was specific for H3K4me3, and was blocked by
phosphorylation at either H3T3 or H3T6 (Figure 4A). From the structure of the Rag2 PHD
domain bound to H3K4me3 peptide[20], it can clearly be seen how H3T3 phosphorylation
may disrupt binding. Timmers and coworkers very recently published that H3T3
phosphorylation acts as a switch to control the binding of TAF3 PHD domain[21]. Thus, this
may be a general mechanism for controlling gene expression during mitosis (when H3T3 is
phosphorylated). Similarly, Denu and coworkers found that H3T6 phosphorylation may
disrupt this binding[22].
We next examined the tandem Bromo–PHD domains of BPTF (subunit of the NURF ATP-
dependent remodeling complex[23]). Our studies showed that the tandem domain was
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specific for H3K4me3 and also showed reduced binding in the presence of either H3T3 or
H3T6 phosphorylation (Figure 4B). However, both Rag2 and BPTF are blocked by
citrulline, but not methylation at position 2, suggesting a role for the positive charge of
H3R2 in PHD domain binding. Notably, converting H3R2 to citrulline results in a loss of
cationic charge and likely loss of ionic and hydrogen bonding interactions within the pockets
of the two PHD domains (Figure 4A and 4B). Interestingly, our ability to synthesize and
print longer peptides allowed us to observe greater interactions of BPTF (PHD-Bromo) with
H3K4me3 peptides also harboring acetylation. We found multiple acteylations on H3
enhanced the binding of BPTF to H3K4me3 (Figure 4B and Figure S2), suggesting
coordination between the methyl-binding PHD domain and the acetyl-binding bromodomain
to recognize multiple modifications on the Histone H3 tail.
The chromodomain of human CHD1 is also known to recognize H3K4me3, but has a
structurally distinct binding pocket from the PHD domains. We found that CHD1, like Rag2
and BPTF, preferentially binds H3K4me3 and is also negatively influenced by
phosphorylation at H3T3 and H3T6 (Figure 4C). Interestingly, we also found that
methylation of H3R2 appears to slightly enhance binding of CHD1 whereas citrullination
blocks this binding. While the finding that H3R2 methylation reduces binding affinity of
human CHD1 to H3K4me3 is in opposition to a previous report [24], this discrepancy may
be due to the fact that Khorasanizadeh and coworkers used peptides labeled at the N-
terminus with fluorescein in their binding studies, which may have contributed to the
binding. Consistent with our CHD1 findings, we and others have found that H3R2
methylation does not decrease CHD1 binding to H3K4me3 by either isothermal titration
calorimetry (data not shown) or by fluorescence polarization using C-terminally labeled
peptides (Marcey Waters personal communication). H3R2 methylation and H3K4me3 have
been found to be mutually exclusive in yeast and humans[25, 26]. Thus, H3R2 methylation
and H3K4me3 may function to prevent the binding of effector proteins that promote gene
transcription while facilitating the recruitment of CHD1 (and possibly other factors) to genes
in order to promote gene silencing.
The complex patterns of histone PTMs are critical determinants of chromatin structure and
function, but also represent a significant challenge for future study. While many protein
domains that bind selectively to particular PTMs have been identified, little is known
regarding how neighboring modifications inhibit or contribute to these interactions. Of equal
importance is our understanding of how patterns of PTMs influence antibody recognition. In
this case, detection of biologically important events could be blocked or misrepresented if
neighboring modifications interfere with epitope recognition. Thus, our work underscores a
need for more rigorous testing and characterization of histone-specific antibodies. The
datasets for the antibodies and proteins described here plus numerous additional antibodies
are available in the supplemental data and from our website
(http://www.med.unc.edu/~bstrahl/Arrays/index.htm). In addition, we will continue to
characterize histone antibody specificities and post the data to our website as an ongoing
resource for chromatin community.
Finally, while several other peptide array approaches have been used to measure binding to
histone PTMs[7,27-29], our arrays are a significant improvement over these other
technologies. Specifically, our array displays a larger number of peptides carrying multiple
PTMs allowing us to measure the influence of neighboring PTMs on binding. Additionally,
we report full characterization of all synthesized peptides. Lastly, the high density of
spotting allows us to perform statistical analysis of binding interactions. Liu et al. recently
reported a similarly semi-quantitative approach, however their arrays were largely limited to
peptides containing single PTMs and the peptides were labeled via their N-terminus, which
could potentially occlude proteins and antibodies from recognizing modifications such as
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H3K4 methylation[28]. In addition, A very elegant bead-based approach has been used to
generate even larger peptide libraries and successfully characterized the binding of several
protein factors to combinatorial histone PTMs[22], however, our approach offers advantages
in that we obtain binding data for each individual peptide and do not require sophisticated
mass spectrometry for analysis. Importantly, post-translationally modified peptides can be
synthesized relatively inexpensively and can also be purchased from commercial sources.
Furthermore slides for peptide immobilization are relatively inexpensive making this
approach feasible for the study of other systems regulated by PTMs as well.
EXPERIMENTAL METHODS
Antibodies
All primary antibodies tested are commercially available and are listed in Table S1.
Secondary antibodies were Alexafluor 647-conjugated goat anti-rabbit IgG (Cat A21244)
and Alexfluor 647-conjugated rabbit anti-mouse IgG (Cat. A21239) antibodies from
Invitrogen.
Peptide Synthesis
All reagents were obtained from commercial suppliers (AnaSpec, EMD, and Apptec). The
peptides, biotinylated at their C-termini, were synthesized on either NovaPEG Rink amide
resin (histone H3 peptides) or Biotin-PEG NovaTag resin (histone H2A, H2B, and H4
peptides) using Fmoc (Fluorenylmethyloxycarbonyl) chemistry on a PS-3 automated peptide
synthesizer (PTI) (See Table S2 for the complete list of peptides). All standard amino acids
were coupled using HATU and N-methylmorpholine in DMF. Fmoc deprotection was
performed using 20% piperidine in DMF. Modified amino acid residues were coupled using
HATU, HOAt, and N,N,-diisopropyletylamine in NMP and the coupling of these residues
was monitored using ninhydrin test and repeated when needed. Peptides were cleaved from
the resins using a 2.5% TIS, 2.5% water in trifluoroacetic acid (TFA). After TFA
evaporation and washing with diethyl ether, the peptides were lyophilized from and
acetonitrile/water solution and purified via preparative HPLC using water-acetonitrile
gradient (0.1%TFA in both solvents) on a Waters SymmetryShield RP-18 5μm 19×150mm
column. All peptides were analyzed using MALDI-TOF MS and analytical HPLC. The
average purity of peptides was over 90% (analytical HPLC). Analytical data for all peptides
mentioned in this paper is available on our website.
Array Fabrication
Biotinylated peptides (25 μM final concentration) in printing buffer (10 mg/ml bovine serum
albumin (Amresco), 0.3% Tween-20, and 10 μM biotin-conjugated fluorescein added to 1X
ArrayIt protein printing buffer) were arrayed onto SuperStreptavidin-coated slides (ArrayIt)
using SMP6 stealth pins (~200 μm spot diameter) and a OmniGrid100 arrayer (Digilab/
Genomic Solutions) at ambient temperature and humidity (50-60%) using the following
printing parameters. To minimize effects from individual pins or localized imperfections in
the substrate arrays, samples were arrayed as a series of six spots, two times on each slide at
a spacing of 375 μm as indicated in Table S3 and each peptide was printed by two different
pins on each slide. After printing, slides were incubated overnight at 4°C in a humidified
environment to facilitate interaction between the biotinylated peptide and the streptavidin
surface. Slides were then blocked for 1 h at 4° C with Biotin-blocking buffer (ArrayIt),
washed three times with phosphate-buffered saline, dried with air, and stored at 4°C and
used within 60 days.
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Antibody dilutions were made in PBS containing 1% BSA (~10 mg/ml) and 0.3% Tween-20
and exact concentration for each array is summarized in Table S4. Antibodies were
incubated with printed slides for 90-180 minutes at 4°C (with the exception of the H3K4me3
monoclonal antibody from Abcam which was incubated overnight) and washed three times
with cold PBS. Arrays were then probed with the appropriate Alexafluor 647–conjugated
secondary antibody (Invitrogen) for 30–60 minutes at 4°C, washed three times with cold
PBS and dried. Arrays were then scanned using a Typhoon TRIO+ imager (GE Healthcare)
at 10μm resolution using the 526nm and 670nm filter sets for the biotin-fluorescein and
secondary antibody respectively. Interactions were quantified using ImageQuant array
software (GE Healthcare).
Protein Binding
Prior to binding, arrays were blocked in PBS containing 5% BSA (~ 50 mg/mL) and 0.3%
Tween-20 for one hour at 4°C to reduce non-specific binding. GST-tagged protein (~25 μM)
in the same buffer was overlaid on each array (200 μl total volume) and incubated in a
hybridization chamber at 4°C overnight. Slides were washed three times with cold PBS.
Anti-GST primary antibody was incubated with slides for 90-180 minutes at 4°C and
washed three times with cold PBS. Arrays were then probed with the Alexafluor 647–
conjugated anti-rabbit secondary antibody (Invitrogen) for 30–60 minutes at 4°C, washed
three times with cold PBS and dried. Arrays were then scanned using a Typhoon TRIO+
imager (GE Healthcare) at 10μm resolution using the 526nm and 670nm filter sets for the
biotin-fluorescein and secondary antibody respectively. Interactions were quantified using
ImageQuant array software (GE Healthcare).
Statistical Analysis
Complete data sets are available for all arrays tested through our online database
(http://www.med.unc.edu/~bstrahl/Arrays/index.htm). Briefly, printing of individual spots
was evaluated based on the intensity of the fluorescein-biotin cospotted with each peptide.
Spots with control intensities of less than 5% of the average intensity for all peptides were
labeled as “not spotted” and omitted from subsequent analysis. Data were treated as four
individual subarrays to account for small changes in intensity across the slide, each subarray
containing all 110 peptides spotted six times. Alexafluor 647 intensities (corresponding to a
positive interaction) were normalized for all spots by dividing the intensity by the sum of all
intensities within a subarray. The six spots for each peptide were averaged (outliers were
removed using a Grubbs test) and treated as a single value for a given subarray. The
normalized intensities for the four subarrays were used to calculate the mean, and the error
is reported as the standard error of the mean. For data displayed as heat maps, mean values
were normalized to either the highest calculated value across all peptides or against the
peptide for which a given antibody was supposed to interact. Heat maps were created using
Java Treeview and all data plotted on a scale from 0 to 1 (Figure S3). Statistical analyses
were performed using Graph Pad Prism software. ANOVA analyses were used to compare
interactions and confidence intervals are reported as 95% (*), 99% (**), or 99.9% (***).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Composition of histone peptide arrays. (A) Peptides synthesized for this study with possible
sidechain modifications (in single or combinatorial fashion) are indicated for each amino
acid. (B) Depiction of array surface. Streptavidin-coated glass slides were spotted with a
library of histone peptides containing different combinations of post-translational
modifications (PTMs) (see also Table S2 for complete peptide list). Biotin-fluorescein was
mixed with the peptides and used as an internal control for spotting efficiency. (C)
Fluorescent image from a sample array. Positive binding interactions are shown as red spots
where only the printing control (green) is visible for negative interactions.
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Antibody binding to histone peptide microarrays. Results of two independent arrays
consisting of 24 independent spots for each peptide are depicted as heatmaps of the
normalized mean intensity and plotted on a scale from 0 to 1 with 1 (yellow) being the most
significant (see Methods). (A) Interactions of H3K4- and H3K79-specific antibodies with
methylated peptides derived from the N-terminus of histone H3 (antibodies used are given in
Table S1 and further information in Figure S1 and S3). (B) Recognition of histone H3
acetyllysine peptides by H3K14ac antibodies. (C) Alignment of sequence surrounding
H3K14 and H3K16. (D) Western blot of yeast whole cell extract probed with H3K14ac
antibody preincubated with various concentrations of histone H3 peptides.
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Effect of neighboring modifications on histone antibody recognition. Results of two
independent arrays consisting of 24 independent spots for each peptide are depicted as
heatmaps of the normalized mean intensity and plotted on a scale from 0 to 1 with 1
(yellow) being the most significant (see Methods). (A) Heatmap of neighboring
modification effect on H3K4me3-specific antibody recognition. (B) Recognition of H3S10
phosphorylation by mono- and dual-specific PTM antibodies. (C) bar graph of data in (B).
Differences in intensities were compared using two-way ANOVA analyses and confidence
intervals (* 95% and ** 99%) are indicated for individual comparisons. Further information
is available in Figure S3.
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Chromatin-associating domain binding to histone peptide arrays. (A) (top) Molecular
representation of the Rag2 PHD domain binding to an H3K4me3-containing peptide (PDB
accession 2V83). (bottom) Heatmap of Rag2 PHD domain binding to histone H3 peptides.
(B) (top) Molecular representation of the BPTF PHD domain binding to an H3K4me3-
containing peptide (PDB accession 2F6J). (bottom) Heatmap of Rag2 PHD-Bromo domain
binding to histone H3 peptides. (C) (top) Molecular representation of the CHD1
chromodomain binding to an H3K4me3-containing peptide (PDB accession 2B2W).
(bottom) Heatmap of CHD1 chromodomain binding to histone H3 peptides. All models were
constructed using PyMol software. Additional information is also contained in Figures S2
and S4.
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